🟢 Context Therapeutics is trading 10% up in pre-market; no clear catalyst identified

Context Therapeutics is trading at $0.35, up 9.72%, with the cause of its September 30 pre-market move unclear.

• No clear company-specific catalyst was identified.
• The latest company press release found was dated September 9 and announced the first patient dosed in the CT-202 Phase 1 trial; available information does not connect that update to this move.
• Supplied major indices are up less than 0.5%, which does not establish a broad-market explanation.